VISX loses Nidek patent decision at ITC (International Trade Commisision):
This article was originally published in Clinica
Executive Summary
The International Trade Commission (ITC) last week decided that Japanese manufacturer Nidek is not infringing VISX's US patents for refractive eye surgery devices. It ruled that one of VISX's key patents was "invalid and unenforceable" and that Nidek did not infringe the other contested patent. As the ITC is not a court, VISX can appeal the decision to the US Court of Appeals in Washington. VISX shares lost more ground, dropping nearly 8% to $16.56. In recent weeks the Santa Clara, California-based VISX has been forced to reduce its fees and is now facing numerous class action suits, alleging charges of securities fraud and insider dealing (see Clinica No 898, p 12).
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.